Barclays PLC Purchases 373,155 Shares of Sanofi (NASDAQ:SNY)

Barclays PLC raised its stake in Sanofi (NASDAQ:SNY - Free Report) by 58.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,012,927 shares of the company's stock after purchasing an additional 373,155 shares during the quarter. Barclays PLC's holdings in Sanofi were worth $48,853,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of SNY. State Street Corp lifted its position in shares of Sanofi by 0.5% during the 3rd quarter. State Street Corp now owns 56,734 shares of the company's stock worth $3,270,000 after buying an additional 264 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after acquiring an additional 16,780 shares during the period. World Investment Advisors LLC boosted its position in Sanofi by 1,020.5% in the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock worth $2,791,000 after purchasing an additional 44,108 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Sanofi in the 3rd quarter valued at $219,000. Finally, Tidal Investments LLC increased its position in shares of Sanofi by 126.7% during the 3rd quarter. Tidal Investments LLC now owns 13,798 shares of the company's stock valued at $795,000 after purchasing an additional 7,711 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

NASDAQ:SNY traded up $0.95 on Wednesday, reaching $52.80. 746,740 shares of the company's stock were exchanged, compared to its average volume of 2,354,999. The stock has a fifty day simple moving average of $54.61 and a 200-day simple moving average of $52.11. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market cap of $133.39 billion, a price-to-earnings ratio of 21.20, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is presently 64.26%.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. BNP Paribas started coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Finally, Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.